Celiac Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Celiac disease is an immune-mediated disorder characterized by small intestinal enteropathy, systemic malabsorption and immune activation symptoms, and autoantibodies to tissue transglutaminase (TTG). It is unique among autoimmune diseases in that the trigger, dietary gluten, has been identified, and removing it results in the resolution of symptoms and enteropathy in most patients. The undiagnosed celiac disease might have severe consequences in children and adult subjects. Celiac disease's primary mechanism is an abnormal adaptive immune response to gluten-derived peptides. Prolamines have been found to contain critical epitopes presented by either HLA-DQ2 or HLA-DQ8 that induce a CD4+ T-lymphocyte response. Celiac disease can be severe as it can cause long-lasting digestive problems and keep the body from getting all the necessary nutrients. It can also affect the body outside the intestine.
·
The prevalence of Celiac disease varies from
450 to 675 cases per 100,000 population in the USA.
Thelansis’s
“Celiac Disease Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2023 To 2033" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Celiac Disease treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights of Celiac Disease across
8 MM market from the centre of Excellence/ Public/ Private hospitals
participated in the study. Insights around current treatment landscape,
epidemiology, clinical characteristics, future treatment paradigm, and Unmet
needs.
Celiac
Disease Market Forecast Patient Based Forecast Model (MS. Excel Based
Automated Dashboard), which Data Inputs with sourcing, Market Event, and
Product Event, Country specific Forecast Model, Market uptake and patient share
uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing
scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Celiac
Disease, Celiac Disease market outlook, Celiac
Disease competitive landscape, Celiac Disease market forecast, Thelansis, Primary market research, KOL
insights, Competitive Intelligence (CI)
Comments
Post a Comment